Enozertinib in EGFR Exon 20ins mutants: a game changer for CNS metastases, or a temporary conquest?
Naoki Furuya · 2026
Read Enozertinib in EGFR Exon 20ins mutants: a game changer for CNS metastases, or a temporary conquest? by Naoki Furuya (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13557853.txt.
Description
ns in vitro and in vivo preclinical models. Amivantamab in combination with carboplatin plus pemetrexed was established in the PAPILLON study for patients with EGFR Ex20ins as the first-line setting (2), and is strongly recommended in current guidelines (3). However, the PAPILLON regimen requires intravenous administration and involves complex management of adverse events (AEs).
Catalog record
| CREATOR | Naoki Furuya |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 9 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |